Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Cisplatin
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Year introduced: 1984(1981)
cisplatin, methionine drug combination [Supplementary Concept]
high doses of cisplatin were tolerated by rats without renal toxicity in the form of cisplatin-methionine complex
Date introduced: June 7, 1994
cisplatin-deoxy(guanosine monophosphate guanosine) adduct [Supplementary Concept]
Date introduced: July 11, 1995
deoxyadenylyl-thymidyl-deoxyguanylyl-deoxyguanosine-cisplatin complex [Supplementary Concept]
Date introduced: August 29, 1984
poly(ethylene glycol)-poly(cisplatin-aspartic acid) [Supplementary Concept]
Date introduced: July 3, 2001
selenium-cisplatin conjugate [Supplementary Concept]
Date introduced: March 11, 1998
SSRP1 protein, human [Supplementary Concept]
RefSeq NM_003146
Date introduced: April 15, 1992
cisplatin-deoxy(adenosine monophosphate guanosine) adduct [Supplementary Concept]
induces mutagenesis in E coli
Date introduced: September 19, 1990
cisplatin-DNA adduct [Supplementary Concept]
Date introduced: November 3, 1988
ethoxysuccinato-cisplatin [Supplementary Concept]
an antineoplastic prodrug; structure in first source
Date introduced: June 29, 2017
CLPTM1L protein, human [Supplementary Concept]
RefSeq NM_030782
Date introduced: March 24, 2001
SPI-77, liposomal [Supplementary Concept]
a dosage form of cisplatin encapsulated in long-circulating Stealth liposomes
Date introduced: March 21, 2001
DCM-Dex-CDDP [Supplementary Concept]
structure in first source
Date introduced: July 25, 2000
LUC7L3 protein, human [Supplementary Concept]
CROP - cisplatin resistance-associated overexpressed protein; a serine/arginine-rich nuclear protein, isolated from cisplatin-resistant cell line; RefSeq NM_016424
Date introduced: February 17, 2000
TP protocol [Supplementary Concept]
chemotherapy protocol consisting of above compounds; used in the treatment of ovarian cancer
Date introduced: March 26, 1998
MEP regimen [Supplementary Concept]
a chemotherapy regimen consisting of above Cisplatin, Epirubicin & Mitomycin; used for treatment of carcinoma of unknown primary origin
Date introduced: March 6, 1998
cisplatin-procaine complex [Supplementary Concept]
a cationic platinum-triamine complex containing a primary amine ligand; has high solubility & anticancer activity as well as the absence of nephrotoxic effects; structure given in second source
Date introduced: April 6, 1993
cisplatin-guanosine adduct [Supplementary Concept]
Date introduced: January 14, 1992
cisplatin-4-methylpyridine [Supplementary Concept]
structure given in first source
Date introduced: March 14, 1991
DVP (cisplatin) [Supplementary Concept]
chemotherapy protocol consisting of above cpds; used in treatment of lymphomas
Date introduced: April 11, 1983